Fei Guo
Impact in
- Virology top 0.5%
- HIV Research and Treatment
- Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
Papers in
- Virology 47
- HIV Research and Treatment 43
-
- HIV/AIDS drug development and treatment 25
- SARS-CoV-2 and COVID-19 Research 9
- Co-authors
- Shan CenLawrence KleimanMeijuan NiuChen LiangJenan SaadatmandFengwen XuJianwei WangXiaoyu Li
- Journals
- Journal of Virology (9 papers)Retrovirology (7 papers)Scientific Reports (6 papers)Journal of Biological Chemistry (6 papers)Virology (5 papers)
- Partner nations
- ChinaCanadaUnited States
In The Last Decade
Fei Guo
97 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 108
- Virology 1.5k
- Infectious Diseases 1.6k
- Immunology 1.3k
- Business and International Management 112
- Molecular Biology 1.8k
Countries citing papers authored by Fei Guo
This map shows the geographic impact of Fei Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Guo more than expected).
Fields of papers citing papers by Fei Guo
This network shows the impact of papers produced by Fei Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Guo. The network helps show where Fei Guo may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 7 | |
| 5 | 2023 | 16 | |
| 6 | 2023 | 42 | |
| 7 | 2022 | 42 | |
| 8 | 2022 | 6 | |
| 9 | 2022 | 75 | |
| 10 | 2021 | 1 | |
| 11 | 2021 | 66 | |
| 12 | 2021 | 1 | |
| 13 | 2020 | 3 | |
| 14 | 2019 | 47 | |
| 15 | 2016 | 10 | |
| 16 | 2015 | 98 | |
| 17 | 2013 | 265 | |
| 18 | 2012 | 26 | |
| 19 | 2011 | 2 | |
| 20 | 2007 | 60 |
About Fei Guo
Fei Guo is a scholar working on Virology, Infectious Diseases, Immunology, Business and International Management and Hepatology, having authored 100 papers that have together received 4.1k indexed citations. Recurring topics across this work include HIV Research and Treatment (43 papers), interferon and immune responses (26 papers), HIV/AIDS drug development and treatment (25 papers), CRISPR and Genetic Engineering (12 papers), Immune Cell Function and Interaction (9 papers), RNA modifications and cancer (9 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and Hepatitis C virus research (8 papers). The work is most often cited by research in Virology (1.5k citations), Infectious Diseases (1.6k citations), Immunology (1.3k citations), Business and International Management (112 citations) and Molecular Biology (1.8k citations). Fei Guo has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Shan Cen, Lawrence Kleiman, Meijuan Niu, Chen Liang, Jenan Saadatmand, Fengwen Xu, Jianwei Wang, Xiaoyu Li, Qinghua Pan and Lili Ren. Their work appears in journals such as Journal of Virology, Retrovirology, Scientific Reports, Journal of Biological Chemistry and Virology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.